Lantern Pharma Inc. is establishing an AI Center of Excellence and Advanced Agentic Labs in Bengaluru, India, marking a major strategic expansion of the company’s global artificial intelligence capabilities. The initiative is designed to industrialise Lantern’s proprietary RADR® AI platform and enhance collaborative opportunities with pharmaceutical and academic partners worldwide.

The Bengaluru center will provide expanded computational infrastructure, deep-technical talent and “follow the sun” development cycles that enable rapid iteration and deployment of advanced AI modules. These capabilities are intended to support both Lantern’s internal research pipeline and a growing roster of biopharma collaborators, allowing continuous development and refinement of complex machine learning models for precision drug discovery.

At the heart of the initiative is the RADR® platform a sophisticated AI engine that integrates hundreds of billions of oncology focused data points and curated machine learning algorithms to accelerate drug discovery, biomarker identification, predictive modelling and clinical trial design. By scaling RADR’s computational depth in Bengaluru, Lantern aims to support advanced large language models (LLMs) and large quantitative models (LQMs) that optimise molecular candidates across therapeutic areas.

The expansion will take place in planned phases. Phase 1 focuses on enhancing AI-driven cancer drug development building on Lantern’s existing oncology capabilities and expanding multi-agentic systems for tasks such as data aggregation, predictive modelling and biomarker signature discovery. In Phase 2, the center’s remit will broaden to include non oncology therapeutic areas such as inflammation, immunology and neurodegenerative diseases, unlocking wider biopharma partnerships and potential revenue streams.

Lantern has already initiated recruitment in Bengaluru, seeking AI engineers, data scientists and computational biologists to build a high performance technical team. The company anticipates that this expansion will remain cash flow neutral while delivering long term operational leverage and global research acceleration from India’s deep talent pool.

According to company leadership, Bengaluru’s thriving tech ecosystem combined with its strength in AI talent and computational research makes it an ideal location to transform RADR from a pioneering drug discovery platform to a scalable, enterprise-grade AI engine powering precision therapeutics around the world.